These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35979822)

  • 21. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration.
    Pullamsetti S; Krick S; Yilmaz H; Ghofrani HA; Schudt C; Weissmann N; Fuchs B; Seeger W; Grimminger F; Schermuly RT
    Respir Res; 2005 Nov; 6(1):128. PubMed ID: 16262900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial and Smooth Muscle Cell Interaction via FoxM1 Signaling Mediates Vascular Remodeling and Pulmonary Hypertension.
    Dai Z; Zhu MM; Peng Y; Jin H; Machireddy N; Qian Z; Zhang X; Zhao YY
    Am J Respir Crit Care Med; 2018 Sep; 198(6):788-802. PubMed ID: 29664678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX-5461 on pulmonary arterial hypertension and associated vascular remodelling.
    Xu X; Feng H; Dai C; Lu W; Zhang J; Guo X; Yin Q; Wang J; Cui X; Jiang F
    Br J Pharmacol; 2021 Apr; 178(7):1605-1619. PubMed ID: 33486761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caspase-4/11-Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension.
    Wu Y; Pan B; Zhang Z; Li X; Leng Y; Ji Y; Sun K; Chen AF
    Hypertension; 2022 Mar; 79(3):536-548. PubMed ID: 34984912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.
    Gueret A; Harouki N; Favre J; Galmiche G; Nicol L; Henry JP; Besnier M; Thuillez C; Richard V; Kolkhof P; Mulder P; Jaisser F; Ouvrard-Pascaud A
    Hypertension; 2016 Apr; 67(4):717-23. PubMed ID: 26902493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic Inhibition of Toll-Like Receptor 9 Ameliorates Pulmonary Hypertension in Rats.
    Ishikawa T; Abe K; Takana-Ishikawa M; Yoshida K; Watanabe T; Imakiire S; Hosokawa K; Hirano M; Hirano K; Tsutsui H
    J Am Heart Assoc; 2021 Apr; 10(7):e019247. PubMed ID: 33787285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoprotegerin Disruption Attenuates HySu-Induced Pulmonary Hypertension Through Integrin αvβ3/FAK/AKT Pathway Suppression.
    Jia D; Zhu Q; Liu H; Zuo C; He Y; Chen G; Lu A
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28077433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
    Grobs Y; Awada C; Lemay SE; Romanet C; Bourgeois A; Toro V; Nadeau V; Shimauchi K; Orcholski M; Breuils-Bonnet S; Tremblay E; Provencher S; Paulin R; Boucherat O; Bonnet S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
    Hadri L; Kratlian RG; Benard L; Maron BA; Dorfmüller P; Ladage D; Guignabert C; Ishikawa K; Aguero J; Ibanez B; Turnbull IC; Kohlbrenner E; Liang L; Zsebo K; Humbert M; Hulot JS; Kawase Y; Hajjar RJ; Leopold JA
    Circulation; 2013 Jul; 128(5):512-23. PubMed ID: 23804254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Magnolol ameliorates pneumonectomy and monocrotaline-induced pulmonary arterial hypertension in rats through inhibition of angiotensin II and endothelin-1 expression.
    Chang H; Chang CY; Lee HJ; Chou CY; Chou TC
    Phytomedicine; 2018 Dec; 51():205-213. PubMed ID: 30466619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy.
    Jerome JR; Deliyanti D; Suphapimol V; Kolkhof P; Wilkinson-Berka JL
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of DP1 Aggravates Vascular Remodeling in Pulmonary Arterial Hypertension via mTORC1 Signaling.
    He Y; Zuo C; Jia D; Bai P; Kong D; Chen D; Liu G; Li J; Wang Y; Chen G; Yan S; Xiao B; Zhang J; Piao L; Li Y; Deng Y; Li B; Roux PP; Andreasson KI; Breyer RM; Su Y; Wang J; Lyu A; Shen Y; Yu Y
    Am J Respir Crit Care Med; 2020 May; 201(10):1263-1276. PubMed ID: 31917615
    [No Abstract]   [Full Text] [Related]  

  • 39. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
    Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
    Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabidiol attenuates pulmonary arterial hypertension by improving vascular smooth muscle cells mitochondrial function.
    Lu X; Zhang J; Liu H; Ma W; Yu L; Tan X; Wang S; Ren F; Li X; Li X
    Theranostics; 2021; 11(11):5267-5278. PubMed ID: 33859746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.